Work With Us
Contact Us
Work With Us
Contact Us
Search
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
Publications
What’s New
Investors
Press Releases
Events
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
Publications
What’s New
Investors
Press Releases
Events
Publications
Publications
A Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class Cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle
June 2, 2025
Click here
Publications
CID-078, an orally bioavailable Cyclin A/B-RxL inhibitor elicits anti-tumor activity in neuroblastoma models
May 27, 2025
Click here
Publications
Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated in part by disruption of the ATR/CHK1 DNA repair pathway
April 29, 2025
Click here
Publications
CID-078, a first-in-class oral Cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft models
December 9, 2024
Click here
Publications
CID-078, a first-in-class oral macrocycle Cyclin A/B-RxL inhibitor, demonstrates anti-tumor activity in E2F-driven cancers
October 23, 2024
Click here
Publications
Orally bioavailable Cyclin A/B RxL macrocycle has antitumor effect in SCLC and NSCLC cell line derived (CDX) and patient derived xenograft (PDX) models
September 9, 2024
Click here
LOAD MORE
Sign up to stay informed
SUBSCRIBE
Subscribe to our News Alerts
By checking the box and pressing the subscribe button , I acknowledge and accept Circle Pharma’s
Privacy Policy
and
Terms of Service.
Subscribe
